These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 33542481)

  • 1. Allogeneic hematopoietic stem cell transplantation for adult patients with t(4;11)(q21;q23) KMT2A/AFF1 B-cell precursor acute lymphoblastic leukemia in first complete remission: impact of pretransplant measurable residual disease (MRD) status. An analysis from the Acute Leukemia Working Party of the EBMT.
    Esteve J; Giebel S; Labopin M; Czerw T; Wu D; Volin L; Socié G; Yakoub-Agha I; Maertens J; Cornelissen JJ; Pigneux A; Shimoni A; Schwerdtfeger R; Labussière-Wallet H; Russell N; Schattenberg A; Chevallier P; Koza V; Foà R; Schmid C; Peric Z; Mohty M; Nagler A
    Leukemia; 2021 Aug; 35(8):2232-2242. PubMed ID: 33542481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT.
    Pavlů J; Labopin M; Niittyvuopio R; Socié G; Yakoub-Agha I; Wu D; Remenyi P; Passweg J; Beelen DW; Aljurf M; Kröger N; Labussière-Wallet H; Perić Z; Giebel S; Nagler A; Mohty M
    J Hematol Oncol; 2019 Oct; 12(1):108. PubMed ID: 31647022
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Blinatumomab-induced lineage switch of B-ALL with t(4:11)(q21;q23) KMT2A/AFF1 into an aggressive AML: pre- and post-switch phenotypic, cytogenetic and molecular analysis.
    Haddox CL; Mangaonkar AA; Chen D; Shi M; He R; Oliveira JL; Litzow MR; Al-Kali A; Hogan WJ; Elliott MA
    Blood Cancer J; 2017 Sep; 7(9):e607. PubMed ID: 29016570
    [No Abstract]   [Full Text] [Related]  

  • 4. Measurable residual disease, conditioning regimen intensity, and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: A registry analysis of 2292 patients by the Acute Leukemia Working Party European Society of Blood and Marrow Transplantation.
    Gilleece MH; Labopin M; Yakoub-Agha I; Volin L; Socié G; Ljungman P; Huynh A; Deconinck E; Wu D; Bourhis JH; Cahn JY; Polge E; Mohty M; Savani BN; Nagler A
    Am J Hematol; 2018 Sep; 93(9):1142-1152. PubMed ID: 29981272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of haploidentical versus matched sibling donors in hematopoietic stem cell transplantation for adult patients with acute lymphoblastic leukemia: a study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.
    Nagler A; Labopin M; Houhou M; Aljurf M; Mousavi A; Hamladji RM; Al Zahrani M; Bondarenko S; Arat M; Angelucci E; Koc Y; Gülbas Z; Sica S; Bourhis JH; Canaani J; Brissot E; Giebel S; Mohty M
    J Hematol Oncol; 2021 Apr; 14(1):53. PubMed ID: 33794963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First report of t(5;11) KMT2A-MAML1 fusion in de novo infant acute lymphoblastic leukemia.
    Tandon S; Shago M; Davidson S; Kanwar N; Fuligni F; Shlien A; Whitlock J; Villani A; Abla O
    Cancer Genet; 2020 Oct; 248-249():31-33. PubMed ID: 32992102
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Allogeneic HCT for adults with B-cell precursor acute lymphoblastic leukemia harboring IKZF1 gene mutations. A study by the Acute Leukemia Working Party of the EBMT.
    Giebel S; Labopin M; Socié G; Beauvais D; Klein S; Wagner-Drouet EM; Blaise D; Nguyen-Quoc S; Bourhis JH; Thiebaut A; Labussière-Wallet H; Charbonnier A; Berceanu A; Diez-Martin JL; Fegueux N; Esteve J; Nagler A; Mohty M
    Bone Marrow Transplant; 2021 May; 56(5):1047-1055. PubMed ID: 33235351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mixed-phenotype acute leukemia with t(4;11)(q21;q23)
    Liu H
    Blood; 2019 Mar; 133(11):1265. PubMed ID: 30872272
    [No Abstract]   [Full Text] [Related]  

  • 9. Achieving Molecular Remission before Allogeneic Stem Cell Transplantation in Adult Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: Impact on Relapse and Long-Term Outcome.
    Lussana F; Intermesoli T; Gianni F; Boschini C; Masciulli A; Spinelli O; Oldani E; Tosi M; Grassi A; Parolini M; Audisio E; Cattaneo C; Raimondi R; Angelucci E; Cavattoni IM; Scattolin AM; Cortelezzi A; Mannelli F; Ciceri F; Mattei D; Borlenghi E; Terruzzi E; Romani C; Bassan R; Rambaldi A
    Biol Blood Marrow Transplant; 2016 Nov; 22(11):1983-1987. PubMed ID: 27492792
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia.
    Spinelli O; Peruta B; Tosi M; Guerini V; Salvi A; Zanotti MC; Oldani E; Grassi A; Intermesoli T; Micò C; Rossi G; Fabris P; Lambertenghi-Deliliers G; Angelucci E; Barbui T; Bassan R; Rambaldi A
    Haematologica; 2007 May; 92(5):612-8. PubMed ID: 17488684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pre-transplant MRD negativity predicts favorable outcomes of CAR-T therapy followed by haploidentical HSCT for relapsed/refractory acute lymphoblastic leukemia: a multi-center retrospective study.
    Zhao H; Wei J; Wei G; Luo Y; Shi J; Cui Q; Zhao M; Liang A; Zhang Q; Yang J; Li X; Chen J; Song X; Jing H; Li Y; Hao S; Wu W; Tan Y; Yu J; Zhao Y; Lai X; Yin ETS; Wei Y; Li P; Huang J; Wang T; Blaise D; Xiao L; Chang AH; Nagler A; Mohty M; Huang H; Hu Y
    J Hematol Oncol; 2020 May; 13(1):42. PubMed ID: 32366260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The RS4;11 cell line as a model for leukaemia with t(4;11)(q21;q23): Revised characterisation of cytogenetic features.
    Ragusa D; Makarov EM; Britten O; Moralli D; Green CM; Tosi S
    Cancer Rep (Hoboken); 2019 Oct; 2(5):e1207. PubMed ID: 32721124
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of pretransplant minimal residual disease after cord blood transplantation for childhood acute lymphoblastic leukemia in remission: an Eurocord, PDWP-EBMT analysis.
    Ruggeri A; Michel G; Dalle JH; Caniglia M; Locatelli F; Campos A; de Heredia CD; Mohty M; Hurtado JM; Bierings M; Bittencourt H; Mauad M; Purtill D; Cunha R; Kabbara N; Gluckman E; Labopin M; Peters C; Rocha V
    Leukemia; 2012 Dec; 26(12):2455-61. PubMed ID: 22555150
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis benefits of a second Allo-HSCT after CAR-T cell therapy in patients with relapsed/refractory B-cell acute lymphoblastic leukemia who relapsed after transplant.
    Cao XY; Zhang JP; Zhao YL; Xiong M; Zhou JR; Lu Y; Sun RJ; Wei ZJ; Liu DY; Zhang X; Yang JF; Lu P
    Front Immunol; 2023; 14():1191382. PubMed ID: 37469510
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic impact of KMT2A-AFF1-positivity in 926 BCR-ABL1-negative B-lineage acute lymphoblastic leukemia patients treated in GIMEMA clinical trials since 1996.
    Piciocchi A; Messina M; Elia L; Vitale A; Soddu S; Testi AM; Chiaretti S; Mancini M; Albano F; Spadano A; Krampera M; Bonifacio M; Cairoli R; Vetro C; Colella F; Ferrara F; Cimino G; Bassan R; Fazi P; Vignetti M
    Am J Hematol; 2021 Sep; 96(9):E334-E338. PubMed ID: 34048072
    [No Abstract]   [Full Text] [Related]  

  • 16. Comparable outcomes in patients with B-cell acute lymphoblastic leukemia receiving haploidentical hematopoietic stem cell transplantation: Pretransplant minimal residual disease-negative complete remission following chimeric antigen receptor T-cell therapy versus chemotherapy.
    Yang TT; Meng Y; Kong DL; Wei GQ; Zhang MM; Wu WJ; Shi JM; Luo Y; Zhao YM; Yu J; Jing RR; Zhao MY; Zhao HL; Huang H; Hu YX
    Front Immunol; 2022; 13():934442. PubMed ID: 36110859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simultaneous involvement of 11q23 translocation resulting in chimeric MLL-AFF1 and a second translocation [t (9;21) (p13; p11.2)] in an infant acute lymphoblastic leukemia patient at relapse: A case report.
    Liu G; Lu X; Kim YM; Wang X; Li S; Liu Y
    Medicine (Baltimore); 2018 May; 97(21):e10874. PubMed ID: 29794792
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurable residual disease status and outcome of transplant in acute myeloid leukemia in second complete remission: a study by the acute leukemia working party of the EBMT.
    Gilleece MH; Shimoni A; Labopin M; Robinson S; Beelen D; Socié G; Unal A; Ganser A; Vitek A; Sengeloev H; Yakoub-Agha I; Tholouli E; Polge E; Mohty M; Nagler A
    Blood Cancer J; 2021 May; 11(5):88. PubMed ID: 33980810
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [A retrospective comparative study of haplotype hematopoietic stem cell transplantation and human leukocyte antigen-matched sibling donor hematopoietic stem cell transplantation in the treatment of acute B-lymphocyte leukemia].
    Wang ZD; Sun YQ; Yan CH; Wang FR; Mo XD; Lyu M; Zhao XS; Han W; Chen H; Chen YY; Wang Y; Xu LP; Wang YZ; Liu YR; Cheng YF; Zhang XH; Liu KY; Huang XJ; Chang YJ
    Zhonghua Xue Ye Xue Za Zhi; 2022 Mar; 43(3):221-228. PubMed ID: 35405780
    [No Abstract]   [Full Text] [Related]  

  • 20. Minimal Residual Disease at First Achievement of Complete Remission Predicts Outcome in Adult Patients with Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia.
    Zhang M; Fu H; Lai X; Tan Y; Zheng W; Shi J; Zhao Y; Lin M; He J; Cai Z; Luo Y; Huang H
    PLoS One; 2016; 11(10):e0163599. PubMed ID: 27695097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.